Is ACA a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Arcosa (ACA) rests on The CRH merger sets the price: A $150 per share all-cash agreement caps most of the upside and defines the risk. The bear case rests on the largest risk is deal failure. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

ACA key stats

At $149.15 on October 22, 2026, Arcosa (ACA) has a market cap of $7.3B, a P/E of 36.8 on trailing earnings (30.4 on forward earnings) and a dividend yield of 0.13%.

Market cap
$7.3B
P/E (trailing)
36.8
P/E (forward)
30.4
EPS (trailing 12 months)
$4.05
Price to book
2.5
Dividend yield
0.13%
Beta
1.08

Market cap, P/E and yield are measured at the $149.15 price on October 22, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Arcosa (ACA)?

The last two weeks for Arcosa, as of November 17, 2026: the price move, the next earnings date, and what analysts changed.

  • ACA closed at $149.15 on October 22, 2026, up 1.5% over the past five trading days (from $147.01).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Arcosa was spun out of Trinity Industries in late 2018 and has spent the years since reshaping itself from a diversified industrial into an infrastructure materials company. It now reports two segments. Construction Products sells aggregates, specialty materials such as recycled asphalt and lightweight aggregate, and construction site support, and generated roughly $357.0 million of revenue in the second quarter of 2026. Engineered Structures builds utility poles and steel structures, wind towers, telecom and traffic structures, and storage tanks, and generated roughly $301.7 million. The portfolio pruning has been aggressive: the steel components business went in 2025, and the barge business was sold on April 1, 2026 for approximately $450 million, producing a pre-tax gain of roughly $359.7 million and moving barge results into discontinued operations. On the other side of the ledger, the roughly $1.2 billion Stavola acquisition in late 2024 added asphalt and aggregates positions in the New York and New Jersey metro market. The defining fact for anyone looking at ACA today is the merger. On June 22, 2026, CRH announced an agreement to acquire all of Arcosa for $150.00 per share in cash, an enterprise value of roughly $8.5 billion, or about 11.5 times 2026 estimated adjusted EBITDA including roughly $175 million of expected run-rate cost synergies by year three. Arcosa filed its definitive proxy on August 3, 2026, and stockholders approved the acquisition at a special meeting on September 4, 2026. The remaining conditions are customary ones, including required regulatory approvals, and the companies still expect to close in the first quarter of 2027. Management has suspended full-year guidance and stopped holding quarterly earnings calls, though in October it began quarterly calls for holders of its 2029 and 2032 senior notes. With the stock near $147 against a $150 offer, up about 38% year to date and 59% over one year as of October 16, 2026, the residual price movement mostly reflects the market's view of deal completion odds and timing, not aggregate volumes in Texas.

The bull case for ACA

1. The CRH merger sets the price

A $150 per share all-cash agreement caps most of the upside and defines the risk. The remaining gap between the market price and the offer is the spread that merger investors trade; it was about $3, or roughly 2%, at the October 16, 2026 close of $147.01. The September 4 stockholder vote has passed, so regulatory clearance and the passage of time to an expected first-quarter 2027 close are what remain. Because guidance is suspended and calls have stopped, ordinary earnings catalysts have largely been switched off.

2. Aggregates pricing over volume

Construction Products revenue grew only about 1 percent in the second quarter of 2026 as aggregates volumes fell mid single digits on Texas rainfall, but adjusted cash gross profit per ton rose roughly 5 percent. That is the aggregates playbook that made CRH interested in the first place: local pits with pricing power that hold margin through soft volume quarters. Two small bolt-on deals in the quarter, totaling roughly $24.9 million, added recycled aggregates in New Jersey and a Colorado entry.

3. Utility structures backlog versus wind tower softness

Engineered Structures grew adjusted EBITDA about 13 percent to roughly $61.4 million as utility structures revenue rose about 12 percent on grid spending, while wind tower revenue fell roughly 19 percent on planned lower volumes. The utility backlog reached a record of about $648.1 million, up roughly 49 percent year to date. Grid hardening and transmission investment is the durable demand story here; wind is the policy-sensitive one.

4. A cleaner, more leveraged balance sheet

The barge and steel components exits leave a business concentrated in materials and structures rather than cyclical transportation equipment. Yahoo Finance shows total debt near $1.51 billion against about $432 million of cash, with a debt to equity ratio near 0.51; the debt includes $400 million of 4 3/8% notes due 2029 and $600 million of 6 7/8% notes due 2032. Operating cash flow of roughly $341 million over the trailing year is offset by heavy capital spending, leaving trailing free cash flow of only about $60 million.

The bear case for ACA

The largest risk is deal failure. If the CRH transaction does not close, whether through antitrust review of overlapping aggregates positions or a financing or regulatory delay past the expected first-quarter 2027 close, the share price would no longer be supported by the $150 offer and could revert toward where it traded before June 2026, well under the current level (the 52-week low is about $91). The stockholder vote is no longer a hurdle after the September 4, 2026 approval. Plaintiffs' firms including Monteverde & Associates have publicized investigations of the merger process; those have been solicitations rather than a filed securities-fraud complaint, but merger-related disclosure suits are common and can add noise. Underlying business risks remain: heavy exposure to Texas and Southwest construction weather and cycles, wind tower demand that depends on federal incentives and utility procurement, and leverage carried since the roughly $1.2 billion Stavola acquisition. Trailing earnings are also distorted by the roughly $359.7 million pre-tax barge gain, so headline trailing figures overstate or muddle ongoing profitability.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ACA already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on ACA

Too few analysts publish on ACA for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The ACA forecast page covers what coverage does exist.

How is ACA valued?

Market cap, P/E and dividend yield at today's price are in the ACA key stats above. The business figures below come from Arcosa's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$2.9B
  • Q2 2026 revenue (continuing ops): ~$658.7M, up ~2% year over year
  • Q2 2026 adjusted EBITDA: ~$145.9M, ~22.1% margin
  • Q2 2026 adjusted EPS: ~$1.13 vs ~$1.18 estimate
  • Merger terms: $150.00 per share cash, ~$8.5B EV, approved by stockholders Sept 4, 2026, close expected Q1 2027

As of October 2026: Operating multiples matter less than usual here because the CRH offer sets the price: at $147.01 the stock sits about 2% below the $150 cash consideration, a spread that pays holders for waiting until the expected first-quarter 2027 close and for the risk the deal breaks. Fiscal 2025 remains the cleanest reference point for the business itself, with revenue of roughly $2.88 billion and EPS of about $4.24, since 2026 results include the barge gain. The dividend is nominal at $0.20 a share a year (declared again in September), a yield near 0.14 percent, and full-year guidance stays withdrawn.

How do you decide if ACA is a buy?

Whether ACA is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold ACA indirectly through an index or sector ETF before adding more.

What would change your mind on ACA

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: The CRH merger sets the price stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the largest risk is deal failure fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the ACA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ACA against your real portfolio and see your actual exposure before deciding.

Your questions about Arcosa

Ask Walnut's AI anything about ACA and see how it fits what you own.

FAQ

Is ACA a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on The CRH merger sets the price, with revenue (ttm) at ~$2.9B. The bear case rests on the largest risk is deal failure. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell ACA?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest risk is deal failure. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.

What is the bull case for ACA?

+

The CRH merger sets the price. A $150 per share all-cash agreement caps most of the upside and defines the risk.

What is the bear case for ACA?

+

The largest risk is deal failure. If the CRH transaction does not close, whether through antitrust review of overlapping aggregates positions or a financing or regulatory delay past the expected first-quarter 2027 close, the share price would no longer be supported by the $150 offer and could revert toward where it traded before June 2026, well under the current level (the 52-week low is about $91). The stockholder vote is no longer a hurdle after the September 4, 2026 approval. Plaintiffs' firms including Monteverde & Associates have publicized investigations of the merger process; those have been solicitations rather than a filed securities-fraud complaint, but merger-related disclosure suits are common and can add noise. Underlying business risks remain: heavy exposure to Texas and Southwest construction weather and cycles, wind tower demand that depends on federal incentives and utility procurement, and leverage carried since the roughly $1.2 billion Stavola acquisition. Trailing earnings are also distorted by the roughly $359.7 million pre-tax barge gain, so headline trailing figures overstate or muddle ongoing profitability.

What does Arcosa do?

+

Arcosa makes infrastructure products (construction aggregates, utility structures, wind towers) and agreed in June 2026 to be acquired by CRH for $150 per share in cash.

What would have to change for ACA to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The CRH merger sets the price) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the largest risk is deal failure) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What company is ACA stock?

+

ACA is the New York Stock Exchange ticker for Arcosa, Inc., a Dallas, Texas infrastructure products company spun off from Trinity Industries in November 2018. It makes construction aggregates and specialty materials and builds engineered structures such as utility poles, wind towers and storage tanks.

Is Arcosa being acquired?

+

Yes. CRH announced on June 22, 2026 an agreement to acquire all of Arcosa for $150.00 per share in cash, valuing the company at roughly $8.5 billion in enterprise value. Arcosa stockholders approved the deal at a special meeting on September 4, 2026. Closing still requires required regulatory approvals and other customary conditions, and is expected in the first quarter of 2027.

What happens to my ACA shares if the CRH deal closes?

+

In an all-cash merger, shares held at closing are typically cancelled and converted into the right to receive the cash consideration, here $150.00 per share, paid through the holder's broker. The stock then stops trading on the NYSE. With the stockholder vote done, closing depends on regulatory approvals and the other remaining conditions, so nothing is final until those are satisfied.

Walnut is informational, not investment advice, and gives no verdict on ACA. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on October 22, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks